Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review.
Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review.
复制标题
癌症疼痛中的透皮丁丙诺啡和芬太尼斑块：网络系统评价。
DOI：
10.2147/jpr.s140320
复制
发表时间：
2017
影响因子：
2.7
通讯作者：
Ganapathi A
中科院分区：
文献类型：
--
作者：
Ahn JS;Lin J;Ogawa S;Yuan C;O'Brien T;Le BH;Bothwell AM;Moon H;Hadjiat Y;Ganapathi A
癌症疼痛的治疗通常基于世界卫生组织（WHO）的三步疼痛缓解阶梯，该阶梯利用具有增加效力的药物的序贯方法。疼痛管理的目标包括优化镇痛、优化日常生活活动、最小化不良反应和避免异常药物服用。此外，建议镇痛方案个体化和简化，以帮助确保患者依从性，并应提供侵入性最小，最简单，最安全的阿片类药物给药途径，以确保充分的镇痛。丁丙诺啡和芬太尼是两种可用于缓解中度至重度癌症疼痛的阿片类药物。关于这些阿片类药物的透皮（TD）制剂的现有临床数据及其满足上述建议的程度进行了系统性审查，旨在为肿瘤学家和疼痛专家提供有关其比较使用的额外信息。由于缺乏直接比较TD丁丙诺啡与TD芬太尼的研究，还以网络方式评价了将这些与其他步骤3阿片类药物进行比较的数据。
Treatment of cancer pain is generally based on the three-step World Health Organization (WHO) pain relief ladder, which utilizes a sequential approach with drugs of increasing potency. Goals of pain management include optimization of analgesia, optimization of activities of daily living, minimization of adverse effects, and avoidance of aberrant drug taking. In addition, it is recommended that analgesic regimens are individualized and simplified to help ensure patient compliance and should provide the least invasive, easiest, and safest route of opioid administration to ensure adequate analgesia. Buprenorphine and fentanyl are two opioids available for the relief of moderate-to-severe cancer pain. Available clinical data regarding the transdermal (TD) formulations of these opioids and the extent to which they fulfill the recommendations mentioned earlier are systematically reviewed, with the aim of providing additional information for oncologists and pain specialists regarding their comparative use. Due to lack of studies directly comparing TD buprenorphine with TD fentanyl, data comparing these with other step-3 opioids are also evaluated in a network fashion.